Keynotes Financial Opiniery is bullish on Aurbindo Pharma has recommended buy rating on the stock with a target price of Rs 906 in its research report dated March 19, 2019.
Keynotes Financial Opiniery's research report on Aurbindo Pharma
Founded in 1986 by Mr. P.V.Ramprasad Reddy, Mr. k. Nityaananda Reddy and a small group of highly committed professionals, Aurbindo Pharma was born of a vision. The company commenced operations in 1988-89 with a single unit manufacturing Semi-Synthetic Penicillin (SSP) at Pondicherry. Aurobindo Pharma became a public company in 1992 and listed its shares on the Indian Stock exchanges in 1995. In addition to being the market leader in Semi-Synthetic Penicillin’s, Aurobindo Pharma has a presence in key therapeutic segments such as neurosciences (CNS), cardiovascular (CVS), anti- retroviral, anti-diabetics, gastroenterology and Anti-biotics. Aurobindo Pharma has evolved into a knowledge driven company manufacturing active pharmaceutical ingredients and formulation products. One of the largest R & D facilities in India, Aurobindo Pharma has 5 research centres spread over 16,000 square feet. Aurobindo Pharma features among the top 2 Pharmaceutical companies in India in terms of consolidated revenues.
On the basis of Discount Cash Flow Valuation Method, we are recommending ‘Buy’ for the stock. Since the stock offers good opportunity, we initiate a ‘BUY’ signal on the stock with 12-month price target of Rs 906/- share an upside of 30% from current levels.Get access to India's fastest growing financial subscriptions service Moneycontrol Pro for as little as Rs 599 for first year. Use the code "GETPRO". Moneycontrol Pro offers you all the information you need for wealth creation including actionable investment ideas, independent research and insights & analysis For more information, check out the Moneycontrol website or mobile app.